Onychomadesis induced by meglumine antimoniate treatment
Keywords:
Nails, leishmaniasis, drug toxicity.Abstract
Leishmaniasis is a common mucocutaneous and visceral disease in our midst. Pentavalent antimony (meglumine antimoniate, Glucantime®) Glucantime) remains the treatment of choice up todate. This paper describes the case of two young brothers who presented onychomadesis as an adverse drugs reaction for cutaneous leishmaniasis, an effect that resolved after treatment discontinuation. Glucantime often causes mild to moderate adverse effects, with rare compromise of the nails.
Author Biographies
Laura Jaramillo, Universidad CES
Médica, residente de Dermatología, Universidad CES, Medellín, Colombia
Margarita Arboleda, Universidad CES
Médica epidemióloga, maestría en Medicina Tropical, Instituto Colombiano de Medicinal Tropical, Universidad CES, Apartadó, Colombia.
References
1. INS. Guía para la atención clínica integral del paciente con leishmaniasis. Bogotá: Instituto Nacional de Salud, Ministerio de la Protección Social; 2010. Fecha de consulta: julio de 2015. Disponible en: www.ins.gov.co.
2. Instituto Nacional de Salud. Estadísticas por SIVIGILA, año 2014 Fecha de consulta: julio de 2014. Disponible en: http://www.ins. gov.co/lineas-de-accion/Subdireccion.
3. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis. 2007;5:150-8.
4. Chu DH, Rubin AI. Diagnosis and management of nail disorders in children. Pediatr Clin North Am. 2014;61:293-308.
5. Tosti A, Piraccini BM. Nail Disorders. En: Bolognia J, Jorizzo JL, Schaffer JV, editors. . Dermatology. Third edition. London: Elsevier Saunders; 2012. p. 1129-47.
6. Daniel CR, Scher RK. Nail changes secondary to systemic drugs or ingestants. J Am Acad Dermatol. 1984;10:250-8.
7. Kocak AY, Koçak O. Onychomadesis in two sisters induced by varicella infection. Pediatr Dermatol. 2013;30:108-9.
8. Hardin J, Haber RM. Onychomadesis: Literature review. Br J Dermatol. 2015;172:592-6.
9. Wortmann GW, Aronson NE, Byrd JC, Grever MR, Oster CN. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Infect Dis Off Publ Infect Dis Soc Am. 1998;27:509-12.
10. Arboleda M, Jaramillo L, Ortiz D, Díaz A. Cutaneous leishmaniasis and multidermatomic herpes zoster. Rev Chil Infectol. 2013;30:680-2.
11. Neves DB da J, Caldas ED, Sampaio RNR. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate. Trop Med Int Health. 2009;14:1515-22.
12. Sadeghian G, Ziaei H, Sadeghi M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singapore. 2008;37:916-8.
2. Instituto Nacional de Salud. Estadísticas por SIVIGILA, año 2014 Fecha de consulta: julio de 2014. Disponible en: http://www.ins. gov.co/lineas-de-accion/Subdireccion.
3. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis. 2007;5:150-8.
4. Chu DH, Rubin AI. Diagnosis and management of nail disorders in children. Pediatr Clin North Am. 2014;61:293-308.
5. Tosti A, Piraccini BM. Nail Disorders. En: Bolognia J, Jorizzo JL, Schaffer JV, editors. . Dermatology. Third edition. London: Elsevier Saunders; 2012. p. 1129-47.
6. Daniel CR, Scher RK. Nail changes secondary to systemic drugs or ingestants. J Am Acad Dermatol. 1984;10:250-8.
7. Kocak AY, Koçak O. Onychomadesis in two sisters induced by varicella infection. Pediatr Dermatol. 2013;30:108-9.
8. Hardin J, Haber RM. Onychomadesis: Literature review. Br J Dermatol. 2015;172:592-6.
9. Wortmann GW, Aronson NE, Byrd JC, Grever MR, Oster CN. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Infect Dis Off Publ Infect Dis Soc Am. 1998;27:509-12.
10. Arboleda M, Jaramillo L, Ortiz D, Díaz A. Cutaneous leishmaniasis and multidermatomic herpes zoster. Rev Chil Infectol. 2013;30:680-2.
11. Neves DB da J, Caldas ED, Sampaio RNR. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate. Trop Med Int Health. 2009;14:1515-22.
12. Sadeghian G, Ziaei H, Sadeghi M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singapore. 2008;37:916-8.
How to Cite
1.
Jaramillo L, Arboleda M. Onychomadesis induced by meglumine antimoniate treatment. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2016 Dec. 1 [cited 2024 Jul. 22];24(4):307-9. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1123
Downloads
Download data is not yet available.
Downloads
Published
2016-12-01
How to Cite
1.
Jaramillo L, Arboleda M. Onychomadesis induced by meglumine antimoniate treatment. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2016 Dec. 1 [cited 2024 Jul. 22];24(4):307-9. Available from: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/1123
Issue
Section
Case Report
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
